Inovio has rallied 860% year-to-date as investors bid up the company’s stock in hopes of the successful development of a vaccine for COVID-19.
On Tuesday, Inovio fell as much as 17.8% after the company released early Phase I data on its INO-4800 COVID-19 vaccine.
The company said 94% of Phase I participants demonstrated an immune response to the vaccine candidate.
Inovio said its vaccine candidate was selected to participate in a non-human primate study as part of the US government’s Operation Warp Speed.
Visit Business Insider’s homepage for more stories.
Inovio’s Tuesday morning release of early-stage data on its COVID-19 vaccine candidate sent shares lower by as much as 17.8%, giving the stock a breather after it rallied 860% year-to-date.
Investors have bid up the company on hopes that its vaccine candidate for COVID-19 proves successful in human trials.
The interim Phase 1 data from Inovio showed that 94% of trial participants demonstrated overall immune response at week six after two doses of INO-4800, according to the company.
Inovio said it plans to add older participants to its vaccine trial and to initiate a Phase 2/3 efficacy trial for INO-4800 later this summer, upon regulatory concurrence.
Read more: We spoke with 3 financial experts, who said to make 4 these trades right now to get ahead of surprising gains when earnings season starts next month
Inovio also said its vaccine candidate was selected to participate in a non-human primate challenge study as part of the US government’s Operation Warp Speed. Vaxart is another company working on a vaccine for COVID-19 that was selected to participate in the same challenge study, which sent its stock soaring.
Operation Warp Speed is a private-public partnership by the federal government designed to speed up the development and production of a COVID-19 …read more
Source:: Business Insider